Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,634 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study.
Mooi J, Chionh F, Savas P, Da Gama Duarte J, Chong G, Brown S, Wong R, Price TJ, Wann A, Skrinos E, Mariadason JM, Tebbutt NC. Mooi J, et al. Among authors: wong r. Clin Cancer Res. 2021 Apr 15;27(8):2159-2167. doi: 10.1158/1078-0432.CCR-20-2714. Epub 2021 Jan 29. Clin Cancer Res. 2021. PMID: 33514526 Clinical Trial.
Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y, Lok SW, Gibbs P, De Boer R, Yeo B, Greenberg S, Barnett F, Knott L, Richardson G, Wong R, Nottage M, Collins IM, Torres J, Lombard J, Johns J, Harold M, Malik L. Kanjanapan Y, et al. Among authors: wong r. Breast Cancer Res Treat. 2020 Nov;184(1):87-95. doi: 10.1007/s10549-020-05825-w. Epub 2020 Aug 10. Breast Cancer Res Treat. 2020. PMID: 32779037
Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data.
Degeling K, Wong HL, Koffijberg H, Jalali A, Shapiro J, Kosmider S, Wong R, Lee B, Burge M, Tie J, Yip D, Nott L, Khattak A, Lim S, Caird S, Gibbs P, IJzerman M. Degeling K, et al. Among authors: wong r, wong hl. Pharmacoeconomics. 2020 Nov;38(11):1263-1275. doi: 10.1007/s40273-020-00951-1. Pharmacoeconomics. 2020. PMID: 32803720
Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer.
Prasanna T, Wong R, Price T, Shapiro J, Tie J, Wong HL, Nott L, Roder D, Lee M, Kosmider S, Jalali A, Burge M, Padbury R, Maddern G, Carruthers S, Moore J, Sorich M, Karapetis CS, Gibbs P, Yip D. Prasanna T, et al. Among authors: wong r, wong hl. Curr Probl Cancer. 2021 Feb;45(1):100637. doi: 10.1016/j.currproblcancer.2020.100637. Epub 2020 Aug 14. Curr Probl Cancer. 2021. PMID: 32826083 Review.
Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status.
Travers A, Jalali A, Begbie S, Semira C, Kosmider S, Ananda S, Wong R, Lee M, Shapiro J, Burge M, Yip D, Torres J, Ma B, Nott L, Dean A, Tie J, Khattak A, Lim S, Wong HL, Gibbs P. Travers A, et al. Among authors: wong r, wong hl. Clin Colorectal Cancer. 2021 Mar;20(1):e21-e34. doi: 10.1016/j.clcc.2020.08.002. Epub 2020 Aug 12. Clin Colorectal Cancer. 2021. PMID: 32919889
Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Tie J, Cohen JD, Lo SN, Wang Y, Li L, Christie M, Lee M, Wong R, Kosmider S, Skinner I, Wong HL, Lee B, Burge ME, Yip D, Karapetis CS, Price TJ, Tebbutt NC, Haydon AM, Ptak J, Schaeffer MJ, Silliman N, Dobbyn L, Popoli M, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. Tie J, et al. Among authors: wong r, wong hl. Int J Cancer. 2021 Feb 15;148(4):1014-1026. doi: 10.1002/ijc.33312. Epub 2020 Oct 6. Int J Cancer. 2021. PMID: 32984952 Free PMC article.
5,634 results